ATE212375T1 - Modifizierter ciliary neurotrophic factor (cntf), und verfahren zu dessen herstellung und verwendung - Google Patents

Modifizierter ciliary neurotrophic factor (cntf), und verfahren zu dessen herstellung und verwendung

Info

Publication number
ATE212375T1
ATE212375T1 AT99911020T AT99911020T ATE212375T1 AT E212375 T1 ATE212375 T1 AT E212375T1 AT 99911020 T AT99911020 T AT 99911020T AT 99911020 T AT99911020 T AT 99911020T AT E212375 T1 ATE212375 T1 AT E212375T1
Authority
AT
Austria
Prior art keywords
production
neurotrophic factor
cntf
ciliary neurotrophic
modified ciliary
Prior art date
Application number
AT99911020T
Other languages
English (en)
Inventor
James P Fandl
Neil Stahl
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Application granted granted Critical
Publication of ATE212375T1 publication Critical patent/ATE212375T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6842—Proteomic analysis of subsets of protein mixtures with reduced complexity, e.g. membrane proteins, phosphoproteins, organelle proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pathology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Food Science & Technology (AREA)
  • Neurosurgery (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Psychology (AREA)
  • Genetics & Genomics (AREA)
  • Obesity (AREA)
AT99911020T 1998-02-27 1999-02-26 Modifizierter ciliary neurotrophic factor (cntf), und verfahren zu dessen herstellung und verwendung ATE212375T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/031,693 US6472178B1 (en) 1998-02-27 1998-02-27 Nucleic acids encoding a modified ciliary neurotrophic factor and method of making thereof
PCT/US1999/004430 WO1999043813A1 (en) 1998-02-27 1999-02-26 Modified ciliary neurotrophic factor, method of making and methods of use thereof

Publications (1)

Publication Number Publication Date
ATE212375T1 true ATE212375T1 (de) 2002-02-15

Family

ID=21860892

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99911020T ATE212375T1 (de) 1998-02-27 1999-02-26 Modifizierter ciliary neurotrophic factor (cntf), und verfahren zu dessen herstellung und verwendung

Country Status (13)

Country Link
US (4) US6472178B1 (de)
EP (1) EP1056856B1 (de)
JP (1) JP4330796B2 (de)
AT (1) ATE212375T1 (de)
AU (1) AU749660B2 (de)
CA (1) CA2320402C (de)
DE (1) DE69900816T2 (de)
DK (1) DK1056856T3 (de)
ES (1) ES2168006T3 (de)
IL (2) IL137858A0 (de)
NZ (1) NZ506267A (de)
PT (1) PT1056856E (de)
WO (1) WO1999043813A1 (de)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040120891A1 (en) * 1998-12-21 2004-06-24 Craig Hill Compounds for intracellular delivery of therapeutic moieties to nerve cells
BR0013204A (pt) * 1999-08-13 2004-02-17 Regeneron Pharma Uso do fator neurotrófico ciliar modificado ax-15, métodos para tratar a diabetes, para reduzir a resistência à insulina, para aumentar a sensibilidade à insulina, para abaixar os nìveis de ácido graxo livre de soro, para tratar uma doença ou distúrbio do sistema endócrino, e para prevenir a ocorrência de diabetes gestacional ou diabetes mellitus não dependente de insulina, em um mamìfero, e, composição
PL211162B1 (pl) * 2001-02-01 2012-04-30 Biogen Idec Inc Polipeptyd wariantu neublastyny, zawierające go białko fuzyjne i sposób ich wytwarzania oraz dimer, kwas nukleinowy, wektor, komórka gospodarza, koniugat, kompozycja farmaceutyczna i zastosowanie
US7442370B2 (en) 2001-02-01 2008-10-28 Biogen Idec Ma Inc. Polymer conjugates of mutated neublastin
EP1234583A1 (de) * 2001-02-23 2002-08-28 F. Hoffmann-La Roche Ag PEG-Konjugate des HGF-NK4
US7105526B2 (en) 2002-06-28 2006-09-12 Banyu Pharmaceuticals Co., Ltd. Benzimidazole derivatives
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US20050064555A1 (en) * 2003-07-09 2005-03-24 Xencor, Inc. Ciliary neurotrophic factor variants
WO2005028438A1 (ja) 2003-09-22 2005-03-31 Banyu Pharmaceutical Co., Ltd. 新規ピペリジン誘導体
EP1734963A4 (de) 2004-04-02 2008-06-18 Merck & Co Inc Verfahren zur behandlung von menschen mit metabolischen und anthropometrischen störungen
US7279282B2 (en) * 2004-07-09 2007-10-09 Scott Mellis Methods for identifying a candidate for treatment of obesity
AU2005272627A1 (en) 2004-08-13 2006-02-23 Amgen Inc. Substituted benzofused heterocycles
ATE472333T1 (de) 2004-08-19 2010-07-15 Biogen Idec Inc Rückfaltung von proteinen der transforming-growth-factor-beta-familie
ES2325773T5 (es) 2004-11-01 2014-02-24 Amylin Pharmaceuticals, Llc. Tratamiento de la obesidad y de los trastornos relacionados
GB0425625D0 (en) * 2004-11-22 2004-12-22 Royal College Of Surgeons Ie Treatment of disease
US7737155B2 (en) 2005-05-17 2010-06-15 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
NZ562766A (en) 2005-05-30 2011-03-31 Banyu Pharma Co Ltd Piperidine derivatives as histamine-H3 receptor antagonists
EP1916239A4 (de) 2005-08-10 2009-10-21 Banyu Pharma Co Ltd Pyridolverbindung
AU2006282260A1 (en) 2005-08-24 2007-03-01 Msd K.K. Phenylpyridone derivative
US20090264426A1 (en) 2005-09-07 2009-10-22 Shunji Sakuraba Bicyclic aromatic substituted pyridone derivative
US8293900B2 (en) 2005-09-29 2012-10-23 Merck Sharp & Dohme Corp Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
US20080255084A1 (en) 2005-10-21 2008-10-16 Randy Lee Webb Combination of Organic Compounds
EP1944301A4 (de) 2005-10-27 2012-01-04 Msd Kk Neue benzoxathiinderivate
CA2629018C (en) 2005-11-10 2013-12-31 Banyu Pharmaceutical Co., Ltd. Aza-substituted spiro derivative
TWI501774B (zh) 2006-02-27 2015-10-01 Biogen Idec Inc 神經性病症之治療
EP2698157B1 (de) 2006-09-22 2015-05-20 Merck Sharp & Dohme Corp. Verfahren zur Behandlung von Fettsäure-Synthese-Hemmern
WO2008038692A1 (en) 2006-09-28 2008-04-03 Banyu Pharmaceutical Co., Ltd. Diaryl ketimine derivative
US8796214B2 (en) * 2007-03-16 2014-08-05 Research Foundation For Mental Hygiene, Inc. Neurotrophic peptides
US8796215B2 (en) * 2007-03-16 2014-08-05 Research Foundation For Mental Hygiene, Inc. Neurotrophic peptides
EP2009103A1 (de) * 2007-03-16 2008-12-31 Ebewe Pharma Ges.m.b.H. Nfg. KG Neurotrophische Peptide
US8592374B2 (en) * 2007-03-16 2013-11-26 Research Foundation For Mental Hygiene, Inc. Neurotrophic peptides
US8106086B2 (en) 2007-04-02 2012-01-31 Msd K.K. Indoledione derivative
JP5583005B2 (ja) 2007-05-01 2014-09-03 バイオジェン・アイデック・エムエイ・インコーポレイテッド 血管新生を増大させるための組成物および方法
MX354786B (es) 2007-06-04 2018-03-21 Synergy Pharmaceuticals Inc Agonistas de guanilato ciclasa utiles para el tratamiento de trastornos gastrointestinales, inflamacion, cancer y otros trastornos.
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
EP2264026A4 (de) 2008-03-06 2012-03-28 Msd Kk Alkylaminopyridinderivate
JPWO2009119726A1 (ja) 2008-03-28 2011-07-28 Ｍｓｄ株式会社 メラニン凝集ホルモン受容体拮抗作用を有するジアリールメチルアミド誘導体
CA2726917C (en) 2008-06-04 2018-06-26 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US20110071129A1 (en) 2008-06-19 2011-03-24 Makoto Ando Spirodiamine-diaryl ketoxime derivative
EP2321341B1 (de) 2008-07-16 2017-02-22 Synergy Pharmaceuticals Inc. Zur behandlung von erkrankungen des magen-darm-trakts, entzündlichen erkrankungen, krebs und anderen erkrankungen geeignete agonisten von guanylatcyclase
WO2010013595A1 (ja) 2008-07-30 2010-02-04 萬有製薬株式会社 ５員－５員又は５員－６員縮環シクロアルキルアミン誘導体
US8410284B2 (en) 2008-10-22 2013-04-02 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
CA2741672A1 (en) 2008-10-31 2010-05-06 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
WO2010075069A1 (en) 2008-12-16 2010-07-01 Schering Corporation Bicyclic pyranone derivatives as nicotinic acid receptor agonists
EP2379547A1 (de) 2008-12-16 2011-10-26 Schering Corporation Pyridopyrimidinderivate und verfahren zu deren anwendung
AU2011218830B2 (en) 2010-02-25 2014-07-24 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
CA2826649C (en) 2011-02-25 2016-07-26 Merck Sharp & Dohme Corp. Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
RU2015106909A (ru) 2012-08-02 2016-09-27 Мерк Шарп И Доум Корп. Антидиабетические трициклические соединения
BR112015019836A2 (pt) 2013-02-22 2017-07-18 Merck Sharp & Dohme composto, composição farmacêutica, e, uso de um composto
EP2970119B1 (de) 2013-03-14 2021-11-03 Merck Sharp & Dohme Corp. Neuartige indolderivate als antidiabetika
WO2014151200A2 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
JP2016514671A (ja) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド グアニル酸シクラーゼのアゴニストおよびその使用
CN105764916B (zh) 2013-06-05 2021-05-18 博士医疗爱尔兰有限公司 鸟苷酸环化酶c的超纯激动剂、制备和使用所述激动剂的方法
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
MX389591B (es) 2014-08-29 2025-03-20 Tes Pharma S R L INHIBIDORES DE ACIDO A-AMINO-ß-CARBOXIMUCONICO SEMIALDEHIDO DESCARBOXILASA
MX2019004321A (es) 2016-10-14 2019-06-12 Tes Pharma S R L Inhibidores de la acido alfa-amino-beta-carboximuconico semialdehido descarboxilasa.
US11072602B2 (en) 2016-12-06 2021-07-27 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
WO2018118670A1 (en) 2016-12-20 2018-06-28 Merck Sharp & Dohme Corp. Antidiabetic spirochroman compounds
WO2020018700A1 (en) 2018-07-18 2020-01-23 Manzanita Pharmaceuticals, Inc. Conjugates for delivering an anti-cancer agent to nerve cells, methods of use and methods of making thereof
CN118496217A (zh) 2018-11-20 2024-08-16 Tes制药有限责任公司 α-氨基-β-羧基己二烯二酸半醛去羧酶的抑制剂

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE903130A1 (en) 1989-09-15 1991-03-27 Regeneron Pharma Ciliary neurotrophic factor
CN1057295A (zh) 1990-03-14 1991-12-25 菲迪安股份有限公司 人睫状神经元营养因子，编码该因子的dna序列，以及以重组技术生产该因子
IL98304A (en) 1990-06-01 2008-08-07 Regeneron Pharma The ciliary neurotrophic factor receptor
EP0668911A1 (de) * 1991-11-11 1995-08-30 FIDIA S.p.A. Synthese und reinigung von unvollständigen und mutierten formen des humanen ciliaren neurotrophen faktors
CA2145535C (en) * 1992-09-25 2007-07-17 Axel Kahn Adenovirus vectors for the transfer of foreign genes into cells of the central nervous system, particularly in brain
US5349056A (en) * 1992-10-09 1994-09-20 Regeneron Pharmaceuticals Modified ciliary neurotrophic factors
AU7204996A (en) * 1995-10-02 1997-04-28 Cytotherapeutics, Inc. Method for treating amyotrophic lateral sclerosis
IT1288388B1 (it) 1996-11-19 1998-09-22 Angeletti P Ist Richerche Bio Uso di sostanze che attivano il recettore del cntf ( fattore neurotrofico ciliare) per la preparazione di farmaci per la terapia
US6391312B1 (en) 1997-01-23 2002-05-21 Sumitomo Pharmaceuticals Co., Limited Remedies for diabetes

Also Published As

Publication number Publication date
AU2976399A (en) 1999-09-15
US20020123462A1 (en) 2002-09-05
JP2002504370A (ja) 2002-02-12
ES2168006T3 (es) 2002-05-16
US7119066B2 (en) 2006-10-10
US6472178B1 (en) 2002-10-29
WO1999043813A1 (en) 1999-09-02
US6767894B1 (en) 2004-07-27
IL137858A0 (en) 2001-10-31
AU749660B2 (en) 2002-07-04
CA2320402A1 (en) 1999-09-02
US20030144199A1 (en) 2003-07-31
DE69900816D1 (de) 2002-03-14
HK1033336A1 (en) 2001-08-24
NZ506267A (en) 2003-04-29
IL137858A (en) 2008-04-13
PT1056856E (pt) 2002-07-31
JP4330796B2 (ja) 2009-09-16
EP1056856B1 (de) 2002-01-23
CA2320402C (en) 2010-10-12
EP1056856A1 (de) 2000-12-06
DE69900816T2 (de) 2002-08-29
DK1056856T3 (da) 2002-05-06

Similar Documents

Publication Publication Date Title
ATE212375T1 (de) Modifizierter ciliary neurotrophic factor (cntf), und verfahren zu dessen herstellung und verwendung
DE69606244D1 (de) Verrfahren zur herstellung von fällungskieselsäure, aluminium-enthaltende fällungskieselsäuren und deren verwendung zur verstärkung von elastomeren
ATE29729T1 (de) Neue insulin-derivate, verfahren zu deren herstellung und deren verwendung sowie pharmazeutische mittel zur behandlung des diabetes mellitus.
ATE186305T1 (de) Perfluoroalkyll ketone, inhibitoren von elastase und prozess zur deren herstellung
EE04221B1 (et) Östrogeeni kasutamine ravimi valmistamiseks füüsiliste seisundite raviks menopausijärgsetel isikutel
DE69626315D1 (de) Vorrichtung zur herstellung von polsterelementen und deren verwendung
DE58906718D1 (de) Kunststeine, verfahren zur herstellung und verwendung derselben.
DE69014074D1 (de) Röntgenraster für medizinische röntgenaufnahmen und verfahren zu dessen herstellung und zu dessen verwendung.
DE69606243D1 (de) Verfahren zur herstellung von fällungskieselsäure, aluminium-enthaltende fällungskieselsäuren und deren verwendung zur verstärkung von elastomeren
DE3879613D1 (de) Schnellrueckstellbares ptfe und verfahren zu dessen herstellung.
DE59103061D1 (de) Verfahren zur herstellung polyolhaltiger dispersionen und deren verwendung.
GR3031250T3 (en) Methods of diagnosing and treating preeclampsia
ATE307203T1 (de) Verwendung eines anti-interleukin-9 antikörpers zur herstellung eines medikamentes zur behandlung von asthma
DE59701378D1 (de) Neue lederbehandlungsmittel, verfahren zu ihrer herstellung und ihre verwendung bei der herstellung foggingarmer leder
DE58908935D1 (de) Kaltvulkanisierbare Siliconkautschukmasse, Verfahren zu ihrer Herstellung und Verwendung.
DE69517191D1 (de) Wasserlösliche derivate epipodophyllotoxine, verfahren zu ihrer herstellung, ihre verwendung als medikament und ihre verwendung zur herstellung eines antikrebsmittels
DE69419666D1 (de) Vorrichtung zum Verhindern der Schaumbildung bei den extrakorporalen Blutbehandlung und Verfahren zur Herstellung der Vorrichtung
TR200200278T2 (tr) Kalsilitik bileşimler
TW200503717A (en) Substituted 1,4-pyrazine derivatives
EP0383171A3 (de) 2,3,23-Trihydroxy-urs-12-en Derivate zur Behandlung von Kognitiven Störungen
DE69315868D1 (de) Copolymerlatex, Verfahren zu dessen Herstellung sowie dessen Verwendung
DE69719930D1 (de) Verfahren zur Herstellung von medizinischen Pflastern zur perkutanen Verabreichung, und Vorrichtung dafür
DE3886936D1 (de) 2,5,6,7-TETRANOR-4,8-INTER-m-PHENYLEN 2-PGI-DERIVATE, VERFAHREN ZUR HERSTELLUNG UND DEREN VERWENDUNG.
DE69915848D1 (de) Verwendung von neohesperidin dc zur herstellung eines medikaments zur vorbeugung bzw. behandlung von krankheiten aufgrund erhoehter blutfettwerte
DE3862788D1 (de) Fluessige oxydationsmodifizierte ethylenische statistische copolymere, verfahren zur herstellung und deren verwendung.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification